Carmichael Gordon 4

What Happened

• Carmichael Gordon, a director of Gyre Therapeutics, was granted a derivative award on 2026-06-10 giving him the right to purchase 40,000 shares of Gyre common stock. The grant shows $0.00 cash paid at grant (i.e., no cash consideration reported in the filing). This was an award/option-style grant, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-10; Form 4 filed: 2026-06-30 (filed 20 days after the transaction).
• Transaction type/code: A (Award/Grant); reported as a derivative right to purchase 40,000 shares at $0.00 consideration in the filing.
• Vesting: The option vests in 12 equal monthly installments through June 10, 2027, subject to continued service (per footnote).
• Shares owned after transaction: Not specified in the information you provided.
• No 10b5-1 plan, tax-withholding, or exercise/sale of shares was indicated in the supplied filing.
• Timeliness: The Form 4 was filed 20 days after the reported transaction date (appears late relative to the typical 2-business-day Form 4 deadline).

Context

• This is a compensation-style option grant that vests over one year. Such grants are commonly used to retain executives or directors and do not by themselves indicate that the insider bought or sold shares in the open market. The filing does not show an exercise price or immediate sale of any shares; the right to purchase will materialize as shares only as portions vest and are exercised.